Matinas BioPharma received notice of non-compliance with NYSE American listing standards due to falling below stockholders' equity requirements. The exchange accepted the company's remediation plan, granting a compliance period through October 2027.
Matinas BioPharma received notice of non-compliance with NYSE American listing standards due to falling below stockholders' equity requirements. The exchange accepted the company's remediation plan, granting a compliance period through October 2027.